WO2023150693A3 - Neuregulin-4 analogs and methods of using thereof in disease treatment - Google Patents
Neuregulin-4 analogs and methods of using thereof in disease treatment Download PDFInfo
- Publication number
- WO2023150693A3 WO2023150693A3 PCT/US2023/061959 US2023061959W WO2023150693A3 WO 2023150693 A3 WO2023150693 A3 WO 2023150693A3 US 2023061959 W US2023061959 W US 2023061959W WO 2023150693 A3 WO2023150693 A3 WO 2023150693A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- neuregulin
- analogs
- methods
- polypeptides
- disease treatment
- Prior art date
Links
- 101800002641 Neuregulin-4 Proteins 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 102100022658 Pro-neuregulin-4, membrane-bound isoform Human genes 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102400000055 Neuregulin-4 Human genes 0.000 abstract 2
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 108060006698 EGF receptor Proteins 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000007515 enzymatic degradation Effects 0.000 abstract 1
- 238000005734 heterodimerization reaction Methods 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compositions of polypeptides are provided, which are analogs of neuregulin-4 and exhibit one or more activities of neuregulin-4, including the ability to induce homodimerization of ErbB4 subunits, the specificity in inducing homodimerization of ErbB4 over heterodimerization of ErbB family subunits. Various polypeptides described herein possess stability against enzymatic degradation. Methods of treating or reducing the likelihood of inflammatory bowel diseases are also provided using polypeptides that are analogs of human neuregulin-4.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263306163P | 2022-02-03 | 2022-02-03 | |
| US202263306159P | 2022-02-03 | 2022-02-03 | |
| US63/306,163 | 2022-02-03 | ||
| US63/306,159 | 2022-02-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2023150693A2 WO2023150693A2 (en) | 2023-08-10 |
| WO2023150693A3 true WO2023150693A3 (en) | 2023-09-28 |
Family
ID=87553000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2023/061959 WO2023150693A2 (en) | 2022-02-03 | 2023-02-03 | Neuregulin-4 analogs and methods of using thereof in disease treatment |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2023150693A2 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020205840A1 (en) * | 2019-04-01 | 2020-10-08 | Eli Lilly And Company | Neuregulin-4 compounds and methods of use |
-
2023
- 2023-02-03 WO PCT/US2023/061959 patent/WO2023150693A2/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020205840A1 (en) * | 2019-04-01 | 2020-10-08 | Eli Lilly And Company | Neuregulin-4 compounds and methods of use |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023150693A2 (en) | 2023-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009164A (en) | N4-hydroxycytidine and derivatives and anti-viral uses related thereto. | |
| MX2022006700A (en) | Polyheterocyclic compounds as mettl3 inhibitors. | |
| ATE390928T1 (en) | COMPOSITIONS FOR TREATING SKIN DISEASES | |
| MX2023012981A (en) | Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use. | |
| CR20220570A (en) | Compositions comprising nanoparticles, method of making and uses thereof | |
| MX2022014924A (en) | Il-17a modulators. | |
| MX2022014925A (en) | Il-17a modulators. | |
| MX2023003678A (en) | Hsd17b13 inhibitors and uses thereof. | |
| CR20210474A (en) | Neuregulin-4 compounds and methods of use | |
| MX2023010711A (en) | Phenalkylamines and methods of making and using the same. | |
| WO2023081830A3 (en) | Compositions and treatments with nirogacestat | |
| MX2023002522A (en) | Novel compounds for use in the treatment of diseases associated with angiotensin ii. | |
| WO2022238565A3 (en) | Modulators of sortilin activity | |
| WO2023150693A3 (en) | Neuregulin-4 analogs and methods of using thereof in disease treatment | |
| MX2022003398A (en) | Immune stimulating micelle composition. | |
| EP4252776A3 (en) | Compositions and methods for treating ocular diseases | |
| BR112022015768A2 (en) | METHODS OF TREATMENT AND PREVENTION OF GRAFT ARRHYTHMIAS | |
| MX2022002437A (en) | Methods for production of human recombinant arginase 1 and uses thereof. | |
| MX2021011183A (en) | Phytoecdysones and the derivatives thereof for use in the treatment of impaired lung function. | |
| WO2020109233A3 (en) | Trmt2a inhibitors for use in the treatment of polyglutamine diseases | |
| MX2021011986A (en) | Methods of treating neuropathic pain. | |
| WO2002053143A3 (en) | Treatment of erectile dysfunction with rho-kinase inhibitors | |
| MX2022010945A (en) | Therapeutic uses of macrocyclic compounds. | |
| Murias et al. | Therapeutic approach to electric burn with platelet rich plasma, grafts and hyperbaric oxygenation | |
| MX2022012404A (en) | Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23750447 Country of ref document: EP Kind code of ref document: A2 |